世界のHIVワクチン市場動向・予測

◆英語タイトル:Global HIV Vaccines Market Development and Forecast to 2027
◆商品コード:DATA70126013
◆発行会社(リサーチ会社):Market Research Future
◆発行日:2016年10月14日
◆ページ数:52
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD4,450 ⇒換算¥489,500見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD6,250 ⇒換算¥687,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarket Research Future社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Market Research Future社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、世界のHIVワクチン市場について調査・分析し、世界のHIVワクチン市場動向、市場予測、セグメント別分析、主要地域別分析(アメリカ市場、ヨーロッパ市場、アジア市場)、世界市場規模、関連企業分析などを含め、以下の構成でお届けいたします。
【レポートの概要】

Report DescriptionIntroduction
Vaccines empower the human immune system to protect against infection or disease. Vaccines against HIV are being developed, and tested in phases of clinical trials. At present, none of the HIV vaccines are commercially available.
More than 30 HIV candidate vaccines have been tried in roughly 60 Phase I/II trials, involving more than 10,000 healthy volunteers. A large portion of these trials have been conducted in the United States & Europe, and a few in developing countries such as Brazil, Peru, China, and Thailand. The outcomes have affirmed the safety of the vaccines, and have given important scientific information to create fresher eras of candidate vaccines with better capacity to induce anti-HIV specific immune responses.
This research report provides in-depth information about the various market segments. It shall also provide qualitative information about the current and upcoming trends in HIV vaccines market, globally.
The market is majorly divided on the basis of phases of clinical trials and regions. Globally, North America commands the largest market share of around 44% of the global market. This large share is majorly attributed to high adoption of various HIV vaccine trials coupled with the technological advancement in the region. North America is one of the important partners for HIV prevention & research for the development of HIV vaccine, as well as for reduction and prevention of HIV. It has been revealed that more than $600 million a year is invested into HIV vaccine R&D, with the major share coming from the US National Institutes of Health. United States was the first country to carry out the first Phase I trial of an HIV candidate vaccine in 1987. Since then, more than 30 distinctive candidate vaccines have been developed by many organizations, utilizing various technologies mostly in the United States.
Growing number of market players, increasing awareness about HIV prevention among various nations, rising prevalence of HIV, and rising funds for HIV vaccines research, are some of the key factors propelling the growth of HIV vaccines market. However, hindrance during HIV vaccine approval process is limiting the market growth to a great extent.
Some of the key players of the market are GlaxoSmithKline plc (U.K.), SANOFI (France), Argos Therapeutics, Inc. (U.S.), Bionor Pharma ASA (Norway), Janssen Global Services, LLC (U.S.), GENECURE LLC (U.S.), GeoVax (U.S.), GENVEC, INC. (U.S.), PaxVax Corporation (U.S.), and Inovio Pharmaceuticals, Inc. (U.S.).

STUDY OBJECTIVES OF HIV VACCINES MARKET DEVELOPMENT AND FORECAST TO 2027
• To provide insights about factors, influencing and affecting the market growth
• To provide present and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries
• To provide present as well as forecast revenue of the market segments based on products, and sub-segments for global HIV vaccines market
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic and ethical factors that influences the global HIV vaccines market

Target Audience
• Pharmaceutical companies
• Research Laboratories
• Hospitals & Clinics
• Service Suppliers
• Potential Investors
• Key executive (CEO and COO) and strategy growth manager

Key Findings
• The global HIV vaccines market is expected to grow at a CAGR of 5.0% between 2017 and 2027, driven by growth from both developed and emerging markets
• North America contributed more than 44% of the total market size in 2017. Emerging markets such as China and India are expected to generate significant demand for HIV vaccines during the period, 2017-2027
As per the MRFR analysis, the global HIV vaccines market is expected to reach $2.7 billion by 2027. The market in Europe is estimated to be around $ 437 million in 2017 and is anticipated to reach $ 757 million by 2027. Asia-Pacific is expected to grow at a moderate pace during the forecast period.
The reports also cover country level analysis:
• Americas
o North America
 US
 Canada
o South America
• Europe
o Western Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Western Europe
o Easter Europe
• Asia-Pacific
o China
o Japan
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific

【レポートの目次】

Table of Contents

1 REPORT PROLOGUE 9
2 INTRODUCTION 11
2.1 DEFINITION 11
2.2 SCOPE OF STUDY: 11
2.2.1 RESEARCH OBJECTIVE 11
2.3 ASSUMPTIONS & LIMITATIONS 11
2.3.1 ASSUMPTIONS 11
2.3.2 LIMITATIONS 11
2.4 MARKET STRUCTURE 12
3 RESEARCH METHODOLOGY 13
3.1 RESEARCH PROCESS 13
3.2 PRIMARY RESEARCH 14
3.3 SECONDARY RESEARCH 14
4 MARKET DYNAMICS 15
4.1 INTRODUCTION 15
4.2 DRIVERS 15
4.2.1 RISING R&D FUNDING FOR HIV VACCINE 15
4.2.2 RISING PREVALENCE OF HIV DUE TO PROSTITUTION 16
4.2.3 INCREASING AWARENESS DUE TO HIV PREVENTION PROGRAMS 17
4.2.4 GROWING NUMBER OF NEW ENTRANTS IN THE MARKET 17
4.3 RESTRAINTS 17
4.3.1 HIV VACCINE APPROVALS 17
4.4 CHALLENGES 18
4.4.1 LACK OF NATURAL IMMUNITY TO HIV 18
4.4.2 VARIABILITY OF HIV TYPES 18
4.4.3 ANIMAL MODEL TRIALS 18
5 MARKET FACTOR ANALYSIS 19
5.1 INVESTMENT OPPORTUNITY ANALYSIS 19
6 GLOBAL HIV VACCINE MARKET, BY CLINICAL TRIALS 20
6.1 INTRODUCTION 20
6.1.1 PHASE I 20
6.1.2 PHASE II 20
6.1.3 PHASE III 21
7 GLOBAL HIV VACCINE MARKET, BY REGION 22
7.1 INTRODUCTION 22
7.2 NORTH AMERICA 23
7.3 EUROPE 24
7.4 ASIA PACIFIC 25
8 COMPETITIVE LANDSCAPE 27
8.1 INTRODUCTION 27
8.1.1 COLLABORATION 27
8.1.2 ACQUISITION 29
8.1.3 AGREEMENT 30
8.1.4 PARTNERSHIP 30
9 COMPANY PROFILE 32
9.1 ARGOS THERAPEUTICS, INC. 32
9.1.1 COMPANY OVERVIEW 32
9.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 32
9.1.3 FINANCIALS 32
9.1.4 KEY DEVELOPMENTS 33
9.2 BIONOR PHARMA ASA 34
9.2.1 COMPANY OVERVIEW 34
9.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 34
9.2.3 FINANCIALS 34
9.2.4 KEY DEVELOPMENTS 35
9.3 JANSSEN GLOBAL SERVICES, LLC 36
9.3.1 COMPANY OVERVIEW 36
9.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 36
9.3.3 FINANCIALS 37
9.3.4 KEY DEVELOPMENTS 37
9.4 GENECURE LLC 38
9.4.1 COMPANY OVERVIEW 38
9.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 38
9.4.3 FINANCIALS 38
9.4.4 KEY DEVELOPMENTS 38
9.5 GEOVAX 39
9.5.1 COMPANY OVERVIEW 39
9.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 39
9.5.3 FINANCIALS 39
9.5.4 KEY DEVELOPMENTS 40
9.6 GENVEC, INC. 41
9.6.1 COMPANY OVERVIEW 41
9.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 41
9.6.3 FINANCIALS 41
9.6.4 KEY DEVELOPMENTS 42
9.7 PAXVAX CORPORATION 43
9.7.1 COMPANY OVERVIEW 43
9.7.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 43
9.7.3 FINANCIALS 43
9.7.4 KEY DEVELOPMENTS 44
9.8 INOVIO PHARMACEUTICALS, INC. 45
9.8.1 COMPANY OVERVIEW 45
9.8.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 45
9.8.3 FINANCIALS 45
9.8.4 KEY DEVELOPMENTS 46
9.9 GLAXOSMITHKLINE PLC 47
9.9.1 OVERVIEW 47
9.9.2 PRODUCT OVERVIEW 47
9.9.3 FINANCIALS 47
9.9.4 KEY DEVELOPMENTS 48
9.10 SANOFI 49
9.10.1 COMPANY OVERVIEW 49
9.10.2 PRODUCT OVERVIEW 49
9.10.3 FINANCIALS 49
9.10.4 KEY DEVELOPMENTS 50
10 APPENDIX 51
10.1 DISCUSSION BLUE PRINT 51

List of Tables
TABLE 1 GLOBAL FACT SHEET BY REGION 2015 22
TABLE 2 GLOBAL HIV VACCINE MARKET, BY REGION 23
TABLE 3 NORTH AMERICA HIV VACCINE MARKET, BY COUNTRY 24
TABLE 4 EUROPE HIV VACCINE MARKET ,BY COUNTRY 25
TABLE 5 ASIA-PACIFIC HIV VACCINE MARKET, BY COUNTRY 26


List of Figures

FIGURE 1 GLOBAL HIV RATES (2014) 10
FIGURE 2 HIV VACCINE R&D INVESTMENT, 2013 16
FIGURE 3 HIV VACCINE CLINICAL PHASES I-III & TIMELINE 20
FIGURE 4 HIV VACCINE CLINICAL TRIALS 21
FIGURE 5 COMPETITIVE LANDSCAPE 27


【掲載企業】

GlaxoSmithKline plc (U.K.), SANOFI (France), Argos Therapeutics, Inc. (U.S.), Bionor Pharma ASA (Norway), Janssen Global Services, LLC (U.S.), GENECURE LLC (U.S.), GeoVax (U.S.), GENVEC, INC. (U.S.), PaxVax Corporation (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), and others.

【レポートのキーワード】

HIVワクチン

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のHIVワクチン市場動向・予測(Global HIV Vaccines Market Development and Forecast to 2027)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆